Biotech News

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

Alkermes plc (ALKS)Alkermes plc2026-05-26 11:00 ESTCompany update

— Company to Present 11 Posters Demonstrating Commitment to Advancing Innovative Research for People Living With Chronic Psychiatric and Neurological Disorders — DUBLIN --(BUSINESS WIRE)--May 26, 2026-- Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data

Open original release

Related news

ALKSAlkermes plc2026-04-16 11:00 EST

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

ALKSAlkermes plc2026-04-14 11:00 EST

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

AXSMAxsome2026-05-26 11:00 EST

Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

TNXPTonix Pharmaceuticals2026-05-28 20:30 EST

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

AXSMAxsome2026-06-04 11:00 EST

Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

TNXPTonix Pharmaceuticals2026-05-26 11:00 EST

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting

HRMYHarmony Biosciences2026-04-16 12:05 EST

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

GHRSGH Research2026-03-25 15:11 EST

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD

NBIXNeurocrine Biosciences2026-06-03 12:30 EST

Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

NBIXNeurocrine Biosciences2026-05-01 20:05 EST

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia

View all latest news

Alkermes plc

Alkermes is a biopharmaceutical company focused on neuroscience, addiction medicine, and specialty therapeutics. Its portfolio combines commercial products and development programs across CNS and related areas.

Recent company news

ALKSAlkermes plc2026-06-04 11:00 EST

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

ALKSAlkermes plc2026-06-03 20:05 EST

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

ALKSAlkermes plc2026-05-26 11:00 EST

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

ALKSAlkermes plc2026-05-21 11:00 EST

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

ALKSAlkermes plc2026-05-12 11:00 EST

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

Stock data

Close: 52.73 USD
Market cap: 6.89B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States